Repositive RT-PCR test in discharged COVID-19 patients during medical isolation observation

Huang, Kun; Li, Wen; Zhou, Jinxia; Wang, Yao; Zhang, Yuxiang; Tang, Xinle; Liang, Jing; Bi, Fangfang

doi:10.7150/ijms.58766

Cited by 6 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether current vaccines are effective against the new Omicron variant of COVID-19 has been investigated: effectiveness of the vaccine against SARS-CoV-2 was lower for omicron than that for pre-omicron variants 1 month after vaccine completion, and little protection remained by 6 months after the primary vaccine series ( Higdon et al, 2022 ). Both re-positives and non-re-positives have been reported to have similar patterns of IgG and IgM ( Huang et al, 2021 ). Therefore, large-scale and multicenter studies are recommended to better understand the pathophysiology of the potential recurrence of SARS-CoV-2 in patients with COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China

Zhu

Zhang

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

China experienced another widespread Coronavirus disease 2019 (COVID-19) outbreak recently caused by the Omicron variant, which is less severe but far more contagious than the other COVID-19 variants, leading local governments to focus efforts on eliminating the spread of the disease. Previous studies showed that after “recovering” from the virus, some patients could re-test positive for COVID-19 with nucleic acid tests, challenging the control of disease spread. In this study, we aimed to analyze the clinical and laboratory characteristics of re-positive COVID-19 patients in Northeast China. We retrospectively analyzed data from confirmed reverse transcription polymerase chain reaction (RT-PCR) re-positive COVID-19 patients who were admitted to the First Hospital of Jilin University, Jilin Province, China, from March to June 2022. Detailed clinical symptoms, medical history, anti-Corona Virus (CoV) IgG and IgM levels, and CoV nucleic acid cycle threshold (Ct) values during the re-positive period were collected and analyzed. A total of 180 patients were included in this study, including 62 asymptomatic cases and 118 mild cases. The cohort included 113 men and 67 women, with an average age of 45.73 years. The median time between recovery from the virus and re-positivity was 13 days. Our results showed that the proportion of re-positive patients with symptoms was lower, and the nucleic acid test-positive duration was shorter during the re-positive period. Furthermore, in patients with underlying disease, the proportion of patients with symptoms was higher, anti-CoV IgG levels were lower, and the total disease duration was longer. In conclusion, during the re-positive period, the symptoms were milder, and the CoV nucleic acid test-positive course was shorter. The concomitant underlying disease is an important factor associated with clinical symptoms, and the overall course of COVID-19 re-positive patients may be associated with lower anti-CoV IgG levels. Large-scale and multicenter studies are recommended to better understand the pathophysiology of recurrence in patients with COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China

Zhu

Zhang

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…The Centers for Disease Control and Prevention currently recognizes quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR) as the diagnostic gold standard for COVID‐19 5–8 . However, this method also has several limitations.…”

Section: Introductionmentioning

confidence: 99%

CRISPR dual enzyme cleavage triggers DNA and RNA substrate cleavage for SARS‐CoV‐2 dual gene detection

Jiang,

Liu,

Shen

2023

Journal of Medical Virology

View full text Add to dashboard Cite

The widespread dissemination of coronavirus 2019 imposes a significant burden on society. Therefore, rapid detection facilitates the reduction of transmission risk. In this study, we proposed a multiplex diagnostic platform for the rapid, ultrasensitive, visual, and simultaneous detection of the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) open reading frame 1ab (ORF1ab) and N genes. A visual diagnostic method was developed using a clustered regularly interspaced short palindromic repeat (CRISPR)‐Cas12a/Cas13a dual‐enzyme digestion system integrated with multiplex reverse transcriptase‐recombinase polymerase amplification (RT‐RPA). Two CRISPR‐Cas proteins (Cas12a and Cas13a) were introduced into the system to recognize and cleave the N gene and ORF1ab gene, respectively. We used fluorescent or CRISPR double digestion test strips to detect the digested products, with the N gene corresponding to the FAM channel in the PCR instrument or the T1 line on the test strip, and the ORF1ab gene corresponding to the ROX channel in the PCR instrument or the T2 line on the test strip. The analysis can be completed in less than 20 min. Meanwhile, we assessed the application of the platform and determined a sensitivity of up to 200 copies/mL. Additionally, dual gene validation in 105 clinical nasopharyngeal swab samples showed a 100% positive predictive value agreement and a 95.7% negative predictive value agreement between our method and quantitative reverse transcription‐polymerase chain reaction. Overall, our method offered a novel insight into the rapid diagnosis of SARS‐CoV‐2.

show abstract

“…A positive RT-PCR test result indicates a confirmed COVID-19 case 6 . Some countries discharge inpatients with COVID-19 if two RT-PCR tests are negative more than 24 h apart 7 . However, the discharge criteria vary widely among countries and some do not have specific discharge criteria 8 .…”

Section: Introductionmentioning

confidence: 99%

A complete blood count-based multivariate model for predicting the recovery of patients with moderate COVID-19: a retrospective study

Wang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Many resource-limited countries need an efficient and convenient method to assess disease progression in patients with coronavirus disease 2019 (COVID-19). This study developed and validated a complete blood count-based multivariate model for predicting the recovery of patients with moderate COVID-19. We collected the clinical data and laboratory test results of 86 patients with moderate COVID-19. These data were categorized into two subgroups depending on the laboratory test time. Univariate logistic regression and covariance diagnosis were used to screen for independent factors, and multifactorial logistic regression was used for model building. Data from 38 patients at another hospital were collected for external verification of the model. Basophils (OR 6.372; 95% CI 3.284–12.363), mean corpuscular volume (OR 1.244; 95% CI 1.088–1.422), red blood cell distribution width (OR 2.585; 95% CI 1.261–5.297), and platelet distribution width (OR 1.559; 95% CI 1.154–2.108) could be combined to predict recovery of patients with moderate COVID-19. The ROC curve showed that the model has good discrimination. The calibration curve showed that the model was well-fitted. The DCA showed that the model is clinically useful. Small increases in the above parameters within the normal range suggest an improvement in patients with moderate COVID-19.

show abstract

Repositive RT-PCR test in discharged COVID-19 patients during medical isolation observation

Cited by 6 publications

References 27 publications

Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China

Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China

CRISPR dual enzyme cleavage triggers DNA and RNA substrate cleavage for SARS‐CoV‐2 dual gene detection

A complete blood count-based multivariate model for predicting the recovery of patients with moderate COVID-19: a retrospective study

Contact Info

Product

Resources

About